GENEROUS Signings Jump From Seven to 40 States in a Week
- CMS announced on 18 September 2026 that all 50 states, the District of Columbia and Puerto Rico have applied to the GENEROUS model, and that 40 states plus Puerto Rico have signed participation agreements. The agency puts the saving at $64.3 billion in taxpayer dollars over ten years.
- Reporting cited by Synopulse on 17 September had 19 states applied and 7 signed. The official count is a different programme: 41 signatories against 52 applicants, with the remaining states holding until the deadline of 30 September 2026.
- The mechanics are unchanged. Participating manufacturers make covered outpatient drugs available at most-favored-nation prices to participating state Medicaid programmes, states invoice manufacturers for supplemental rebates, CMS monitors pricing accuracy, and CMS shares in the rebates through a reduction in the federal share of Medicaid payments.
- CMS Innovation Center Director Abe Sutton said reducing even a fraction of Medicaid drug spending frees state money for education and infrastructure. The release names no participating manufacturer, and the model launched in January 2026 for a five-year run.
Access read
The state question is closed. Forty of fifty signed, and the ten holdouts have ten days. The number CMS did not publish is the one that decides whether the model moves money.
- A manufacturer list is the only thing still missing. States cannot invoice a supplemental rebate to a company that has not signed. CMS has now published state participation twice and manufacturer participation zero times, while 3 companies named on its own model page, AstraZeneca, Pfizer and EMD Serono, have announced agreements without the agency confirming terms.
- $64.3 billion over ten years is stated, not shown. The release gives the figure without the drug count, the price basket or the participation assumption behind it. A saving of that size implies portfolio-wide pricing rather than the selected-drug commitments visible in company filings, and those two readings differ by an order of magnitude.
- Wider state coverage raises the value of the Best Price carve-out, not the cost of it. CMS has confirmed that supplemental rebates under the model leave Medicaid Best Price unchanged, so 340B ceiling prices do not move. At 7 states that concession was worth little. At 41 signatories it is what lets a manufacturer price to nearly the whole Medicaid book at international levels without repricing anything else.